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Acute promyelocytic leukemias (APLs) are characterized by the
expression of the PML-RARA oncogene, which is a product of the
15;17 chromosomal translocation. Two lines of evidence suggest
that this genetic alteration is involved in the initiation of
promyelocytic leukemogenesis in vivo: i) the t(15;17) often
represents the only cytogenetic abnormality in an otherwise-
normal karyotype; ii) PML-RARA is able to initiate leukemogenesis
in mouse models on expression in hematopoietic stem cells
(HSCs) or progenitors, giving rise to a disease that recapitulates
clinical and morphological features of human APLs.1 APL onset in
mice, however, occurs after a long latency and with a low
penetrance, suggesting that, like other cancers, APL is a multistep
disease, whereby PML-RARA cooperates with secondary mutations
for the full development of the leukemia phenotype. Notably, in
the pre-leukemic phase of the disease, PML-RARA expression
induces DNA damage in HSCs/progenitors and activates DNA
repair, thus imparting a mutator phenotype that might contribute
to disease progression.2,3
Next-generation sequencing represents a powerful tool for the
discovery of genetic alterations at high resolution. To identify
gene mutations that might cooperate with PML-RARA in the
leukemogenic process, we performed whole-exome sequencing
of 5 leukemias that developed in PML-RARA transgenic mice
(mouse APLs; mAPLs) and 11 patients’ leukemias expressing
PML-RARA (human APLs; hAPLs) (Supplementary Table 1). For the
scope of this investigation, we only considered non-synonymous
single-nucleotide variants (SNVs) and small insertions/deletions
(indels) occurring in the tumor DNA with an allelic frequency
X25% (corresponding to a 450% frequency of cells carrying the
mutation in the tumor sample, assuming the majority of
mutations to be heterozygous). These experimental conditions
allow identiﬁcation of SNVs with a validation rate of 100%, as
shown by an independent sequencing approach (Sanger sequen-
cing; unpublished). We identiﬁed a total of 18 mutations in the
5 mAPLs (16 SNVs and 2 indels) and 73 mutations in the 11 hAPLs
(59 SNVs and 14 indels) (Table 1 and Supplementary Table 2). We
validated all the 16 mAPL SNVs by Sanger sequencing (the 2 indels
were not ampliﬁable for technical reasons), 18/18 randomly
selected human SNVs and 1/1 indel (Supplementary Table 2).
We next combined the results of our sequencing analyses with
those previously published for APLs (1 mAPL and 24 hAPLs),4–7
obtaining a data set of 41 APL samples (6 mAPLs and 35 hAPLs).
Analysis of this data set showed a total of 270 mutations affecting
248 human genes (231 SNVs, 34 indels and 5 splice junction
mutations—SJMs), with a low frequency of mutations per case
(B7.1 in hAPLs and B3.5 in mAPLs). In three cases (two mAPLs
and one hAPL), we found no SNVs or indels with a frequency
higher than 25%. Surprisingly, two hAPL samples showed several
hundreds of low-frequency mutations, whose signiﬁcance remains
unclear (not shown).
Of the 248 mutated genes, 9 were found in X2 patients
(recurrent mutations), and 8 showed a signiﬁcantly higher
mutation rate (qo0.005; FLT3; WT1; KRAS; CALR; CSMD1; DDR2;
REV3L and TCERG1L; Table 2 and Supplementary Table 3). FLT3 and
KRAS have been already described as cooperators of PML-RARA in
mouse models of APLs,8 whereas WT1 is infrequently mutated
in hAPLs.9 Of the remaining ﬁve, the DDR2 (discoidin domain
receptor 2) tyrosine kinase is mutated in a small subset of
squamous cell lung cancer. Notably, DDR2 mutations are critical
oncogenic events for these tumors and confer high sensitivity to
the multi-targeted kinase inhibitor dasatinib.10 We found a total of
25 mutations affecting these eight genes (APL driver mutations),
with FLT3 and WT1 being the most frequently involved (Table 2).
We next investigated the APL speciﬁcity of the identiﬁed
mutations, as compared with other subgroups of acute myeloid
leukemias (AMLs). First, we generated a data set of mutations
in all the available AML samples (n¼ 206; 196 previously
published samples7,11–14 and 10 new samples from this study
(Supplementary Tables 1 and 2)) and divided the AML samples in
different genetic/cytogenetic subgroups: i) samples with muta-
tions of nucleophosmin (NPM1þ : 58 cases); ii) normal karyotype
without NPM1 mutations (NK-NPM1 : 58 cases); iii) complex
karyotype (n¼ 22); iv) translocations or inversions affecting
CBFB/MYH11 (n¼ 11); v) t(8;21) RUNX1/RUNX1T1 (n¼ 7); vi)
trisomy 8 (n¼ 8); vii) MLL-X translocations (n¼ 10). Twenty-seven
cases did not fall into any of these categories (‘Other’).
As for PML-RARA, indirect evidence from mouse models
suggests that mutated NPM115 and fusion proteins of CBFB,
RUNX1 and MLL are initiating mutations for AMLs (reviewed in
McCormack et al.8).
AML mutations were separately analyzed in each of the
AML subgroups. We found a total of 1360 mutated genes
(B9 mutations per case), of which 153 were recurrently mutated
(X2 patients in the same subgroup) and 40 showed a
signiﬁcantly higher mutation rate (qo0.005; Table 2 and
Supplementary Table 3). Notably, included in the 40 genes
were 21 of the 22 signiﬁcantly mutated genes identiﬁed in a
recent analysis of 200 AMLs (also part of our data set7), and
additional mutated genes critical for AMLs (BCOR, ASXL1,
GATA2, SUZ12 and DDX41) or for selected epithelial cancers
(CTCF, PLCE1 and CHD4). The most frequently mutated genes
were also signiﬁcantly associated with speciﬁc AML subgroups:
FLT3, IDH1, DNMT3A and PTPN11 with NPM1þ AMLs; RUNX1,
CEBPA and GATA2 with NK-NPM1 AMLs; TP53 with AMLs with
complex karyotypes; KIT with CBFB/MYH11 AMLs; IDH1 with
AMLs with trisomy 8 (Table 2). Moreover, mutations in SF3B1,
PTPN11, DNAH9, are present in both human and mouse
leukemias.
We then analyzed the distribution of the signiﬁcantly mutated
APL and AML genes (n¼ 44) across all samples (n¼ 239). Twenty-
eight genes (B64%) were mutated in more than one cytogenetic
subgroup, covering 383 of the 416 mutations identiﬁed in all
samples (B92%). In the remaining 16 genes (B36%), mutations
were instead associated with a speciﬁc subgroup, corresponding
to just 33 of the identiﬁed mutations (B8%) and suggesting that
subgroup speciﬁcity might be due to their low frequency. Indeed,
we found a signiﬁcant correlation between frequency of muta-
tions per gene and numbers of subgroups where it is mutated
(Spearman’s coefﬁcient value of 0.93). As regards APLs, 5 of the 8
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signiﬁcantly mutated genes were also found in other AML
cytogenetic subgroups (FLT3; WT1; KRAS; CSMD1 and DDR2),
covering a total of 100 mutations, while 3 (CALR; REV3L and
TCERG1L) were only found in APLs, covering 6 mutations.
Three genes that were found signiﬁcantly mutated in other
AML subgroups were also mutated in APLs (PHF6, FAM5C and
PTPN11).
Together, these results imply that different myeloid leukemias,
including APLs, share the same subset of cooperating mutations,
and are consistent with a scenario whereby speciﬁc initiating
mutations interact with a common pool of highly heterogeneous,
yet phenotypically equivalent, cooperating mutations. Indirect
evidence, however, suggests that the pool of cooperating
mutations in AMLs is not yet entirely deﬁned, and that sequencing
of additional AMLs is needed. In fact, due to the limited size of
some samples (for example, in selected AML subgroups such as
those with rearrangements of CBFB, RUNX1 or MLL), it is likely that
our statistical analyses do not allow the identiﬁcation of all the
driver mutations in AML. Among all the mutated genes (n¼ 1559),
B3% (n¼ 45) were mutated at statistically signiﬁcant frequency
(driver mutations). Among the others (passenger mutations),
however, we identiﬁed mutations that have been causally
implicated in the pathogenesis of AMLs (for example, ETV6,
JAK2, NOTCH1, NUMA1, PRDM16, CBL, CBFB, CHIC2, ELF4, NSD1 and
PDGFRB) or other cancers (for example, PTEN, MYC, ARID1A, SF3B1,
EGFR, NF1, THRAP3, MED12, KDR, IKZF1, DAXX and SETD2).
Table 1. Mutations identified by next-generation sequencing in APLs
Cases Mutations Study
nsSNVs Indels SJMs Total
Mouse APLs
mAPL#Mi1 0 0 0 0 Present
mAPL#Mi2 1 0 0 1 Present
mAPL#Mi3 9 1 0 10 Present
mAPL#Mi4 6 1 0 7 Present
mAPL#Mi5 0 0 0 0 Present
mAPL 3 0 0 3 Wartman et al.4
Total mutations (per Pt.) 19 (3.16) 2 (0.33) 0 21 (3.50) 6 cases total
Human APLs
hAPL#Mi1 5 0 0 5 Present
hAPL#Mi2 13 3 0 16 Present
hAPL#Mi3 2 1 0 3 Present
hAPL#Mi4 3 3 0 6 Present
hAPL#Mi5 0 0 0 0 Present
hAPL#Mi6 5 1 0 6 Present
hAPL#Mi7 12 2 0 14 Present
hAPL#Mi8 1 1 0 2 Present
hAPL#Mi9 4 1 0 5 Present
hAPL#Mi10 7 1 0 8 Present
hAPL#Mi11 7 1 0 8 Present
hAPL#1 5 2 0 7 Greif et al.5
hAPL#2 3 0 0 3 Greif et al.5
hAPL#3 4 0 0 4 Greif et al.5
hAPL 12 0 0 12 Welch et al.6
TCGA-AB-2803 12 1 0 13 TCGA7
TCGA-AB-2804 7 1 0 8 TCGA7
TCGA-AB-2823 0 1 0 1 TCGA7
TCGA-AB-2840 0 1 0 1 TCGA7
TCGA-AB-2841 4 0 0 4 TCGA7
TCGA-AB-2862 7 0 0 7 TCGA7
TCGA-AB-2872 9 1 0 10 TCGA7
TCGA-AB-2897 5 0 1 6 TCGA7
TCGA-AB-2905 15 2 0 17 TCGA7
TCGA-AB-2906 9 1 0 10 TCGA7
TCGA-AB-2980 3 1 0 4 TCGA7
TCGA-AB-2982 1 1 0 2 TCGA7
TCGA-AB-2991 10 0 0 10 TCGA7
TCGA-AB-2994 6 1 0 7 TCGA7
TCGA-AB-2997 9 1 0 10 TCGA7
TCGA-AB-2998 4 1 0 5 TCGA7
TCGA-AB-2999 9 0 0 9 TCGA7
TCGA-AB-3001 8 0 2 10 TCGA7
TCGA-AB-3007 5 1 1 7 TCGA7
TCGA-AB-3012 6 2 1 9 TCGA7
Total in hAPLs (per Pt.) 212 (6.06) 32 (0.91) 5 (0.14) 249 (7.11) 35 cases
Total hþmAPLs (per Pt.) 231 (5.63) 34 (0.83) 5 (0.12) 270 (6.59) 41 cases
Abbreviations: APL, acute promyelocytic leukemia; h, human; indels, small insertion/deletions; m, mouse; nsSNV, non-synonymous single nucleotide variant;
per Pt., per patient; SJM, splice junction mutation; TCGA, The Cancer Genome Atlas.
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